PeppiLibrary

Cognitive

DiHexa peptide reference

Angiotensin IV analog. Reportedly potent BDNF/HGF signal in animal cognitive models.

Last reviewed May 6, 2026 Human data Not FDA approved
Peppi reviewing DiHexa notes
Default dose label8 mg
Preferred routeOral (engineered for this)
Frequency label1× daily
Storage window30 days mixed

Evidence snapshot

Human data

Evidence maturityHuman data
Animal studies only; no published human clinical data

Research chemical

Route map

How records are usually labeled

1 Oral
2 SubQ
3 Transdermal

N/A — oral primary route.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C.
After mixRefrigerate 2–8 °C, use within 30 days.
Use-by cue30 days after mixing
Mixed vial window30 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 25 mg vial
Dose 8 mg
Route Oral (engineered for this)
Review 30d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for DiHexa. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

DiHexa is a synthetic angiotensin IV analog developed at Washington State University, designed for oral bioavailability and CNS penetration. Animal studies report strong synaptogenic effects via the hepatocyte growth factor (HGF)/c-Met pathway. Suppliers and online communities have promoted it heavily for cognitive enhancement; published human data is essentially absent.

Also known as: PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide.

Cognitive enhancement researchSynaptogenesis / neuroplasticity research

Mechanism and timing snapshot

Potentiates hepatocyte growth factor / c-Met signalling; increases dendritic spine formation and synaptogenesis in animal hippocampus. Modified amino acids resist proteolysis and confer oral activity.

Onset labelNot listed
Catalog onset field, when available.
Half-life label4 hr
Engineered for oral bioavailability and resistance to peptidases
Duration label24 hr
Catalog duration field, when available.
oral Moderate (engineered)
subQ High
transdermal Variable

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose8 mg
Catalog dose range4 mg - 25 mg
Default routeOral
Frequency label1× daily
Best time labelMorning.
Food noteLipid carrier (e.g., DMSO/ethanol) often used to aid absorption.

Catalog protocol note

8–25 mg orally daily for 4–8 weeks. No standardised human protocol exists.

Routes and site notes

Available route labelsOral, SubQ, Transdermal
Preferred route labelOral (engineered for this)
Common site labelsNot listed
Site rotation noteN/A — oral primary route.

Chemistry

SequenceNorleucine-Tyrosine-Isoleucine-(6-aminohexanoic acid)-Histidine-Proline-Phenylalanine (modified Ang IV)
Amino acids6
Molecular formulaC40H62N8O8
Molecular weight782.99 Da

Vial, reconstitution, and storage

Supply formPowder (oral) or solution
Typical vial size25 mg
DiluentDMSO/ethanol or pre-formulated tincture
Diluent volume5 mL
Concentration note25 mg in 5 mL → 1.6 mL = 8 mg dose.
Before reconstitutionRefrigerate 2–8 °C.
After reconstitutionRefrigerate 2–8 °C, use within 30 days.
Reconstituted shelf life30 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Largely unknown in humans
  • Anecdotal: headache, mild irritability
  • Unknown

Contraindications and warnings

  • Pregnancy
  • Active malignancy (HGF/c-Met pathway is mitogenic)
  • Human safety data is essentially absent.
  • HGF/c-Met activation has theoretical cancer-promotion concerns.

Other considerations

  • Treat as truly experimental — most published data is in rodents.
  • Online enthusiasm exceeds the published evidence.
  • Discontinue if you have any history of malignancy and discuss with a clinician.

Evidence and regulatory context

Evidence levelAnimal studies only; no published human clinical data
FDA approvedNo
Regulatory statusResearch chemical
Prescription requiredNo
Approved countriesNot listed

Stacking and cycle notes

Stacks well withNot listed
Avoid combining noteNot listed
Typical cycle label2–4
Typical break label2–4
Cycle guidanceShort courses recommended given limited safety data.

Tracking tips

  • Be skeptical of online enthusiasm — human safety data is virtually absent.
  • Theoretical cancer concern via HGF/c-Met activation; not for users with malignancy history.
  • Short cycles only, not chronic supplementation.

References

Track it in Peppi

Keep DiHexa records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for DiHexa?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use DiHexa?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export DiHexa records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026